Benefits
Bone health (small bone-density gain; fracture benefit from supplements is weak)
Calcium is an essential structural mineral of bone, and getting enough matters most for people whose diets are low in it. Food is the first route. For supplements taken on top of an adequate diet, the fracture evidence is weak and inconsistent. Supplements slow bone loss modestly (roughly 0.5 to 2 percent more bone density than placebo after several years). A 2007 meta-analysis of 17 fracture trials found 12 percent fewer fractures overall, rising to 24 percent in trials where people took the pills reliably. A 2016 meta-analysis of 8 calcium plus vitamin D trials, funded by supplement industry trade associations, reported 15 percent fewer total and 30 percent fewer hip fractures in mixed community and residential-care populations. But a 2015 BMJ review found no fracture reduction in the trials at lowest risk of bias, and a 2017 JAMA meta-analysis of 33 trials in community-dwelling adults over 50 found no reduction in hip or other fractures. In the 2015 review, the only single trial with a clear fracture benefit was in frail elderly women in residential care with low calcium intake and low vitamin D.
Cardiovascular concerns: supplements vs dietary calcium
Several analyses since 2010 have reported that calcium supplements modestly increase cardiovascular events. A 2011 BMJ analysis found about 24 percent more heart attacks, and a 2021 pooled analysis of 13 double-blind trials (28,935 people, mostly postmenopausal women) found relative risks of 1.15 for cardiovascular disease and 1.16 for coronary heart disease. A 2016 review of 4 trials and 27 observational studies, paid for by a grant from Pfizer Consumer Healthcare (then a calcium supplement maker) given through the National Osteoporosis Foundation, found no significant difference in the trials and concluded that intake within the upper limit is not associated with cardiovascular risk. The signal is repeated but contested, and the pooled analyses draw largely on the same older trials. Cardiovascular events were secondary outcomes in every trial. Cohort studies have not shown a consistent signal for calcium from food, so the concern applies to supplements.
Calcium in pregnancy: WHO guidance and newer large trials
WHO guidance has recommended 1.5 to 2 g/day of calcium in pregnancy for women in populations with low dietary calcium intake. Two large 2024 trials in India and Tanzania (11,000 first-time pregnant women in each) found 500 mg/day was noninferior to 1,500 mg/day for pre-eclampsia, but both groups took calcium, and in Tanzania the low dose was not noninferior for preterm birth. The 2025 Cochrane update, which set aside trials with trustworthiness concerns, found calcium versus placebo may make little to no difference to pre-eclampsia (RR 0.83, 95% CI 0.67 to 1.04). Limited to the large trials, the evidence was high certainty and again showed little to no difference (RR 0.92), whatever the baseline calcium intake. Pregnant women should follow their prenatal clinician's advice rather than self-dose.
Muscle function and neuromuscular signaling
Calcium plays a central role in excitation-contraction coupling at the neuromuscular junction — sarcoplasmic reticulum calcium release directly drives muscle contraction. Adequate serum calcium is essential for normal muscle function. Hypocalcemia causes tetany, cramps, and numbness. Most people maintain serum calcium tightly through bone storage even with inadequate dietary intake — supplementation rarely fixes muscle symptoms in otherwise healthy adults.
Blood pressure (small effect in people with normal blood pressure)
In a 2022 Cochrane review of 18 trials in 3,140 people with normal blood pressure, increasing calcium intake lowered systolic pressure by about 1.4 mmHg and diastolic by about 1.5 mmHg. The effect was somewhat larger in people under 35 and was similar regardless of baseline calcium intake. No trial reported whether this prevents hypertension. Whole-diet patterns such as DASH have shown larger reductions than calcium alone.
Dental health and tooth structure
Calcium is the primary mineral component of tooth enamel and dentin. Adequate calcium intake during tooth development (childhood and adolescence) supports permanent tooth strength. In adults, dietary calcium plus fluoride and adequate vitamin D supports enamel remineralization. Limited evidence that adult calcium supplementation prevents tooth decay beyond meeting RDA.
Calcium in sweat and sports drinks (no hydration benefit shown)
Calcium is lost in sweat in small amounts compared with sodium. Some sports drinks add calcium, but no trial has shown that it improves hydration or exercise performance, and sodium is the main electrolyte for fluid balance during exercise. Small randomized trials in competitive cyclists have instead looked at bone markers: a calcium-rich dairy meal 2 hours before a 90-minute ride blunted the rise in parathyroid hormone and a bone-breakdown marker, while a 1,000 mg calcium chew 30 minutes before a time trial did not change the bone-breakdown marker. These are short-term blood markers, not bone-density or fracture outcomes.
Food vs supplement (important distinction)
Most cardiovascular concerns apply to supplemental calcium (with or without vitamin D), not dietary calcium from dairy, leafy greens, or fortified foods. Calcium from food is absorbed gradually with meals, while a supplement raises blood calcium more sharply for a few hours; whether that contributes to calcification in blood vessels is a hypothesis, not an established effect. The usual advice is to meet calcium needs from food first and to consider a supplement only if your diet falls well short of the recommended intake.
Mechanism of action
Bone mineralization and remodeling
About 99% of body calcium is stored as hydroxyapatite in bone matrix. Bone is metabolically active — continuously remodeled by osteoclasts (resorption) and osteoblasts (formation). Adequate calcium supports the formation phase; vitamin D enables intestinal absorption. Without adequate calcium and D, parathyroid hormone mobilizes calcium from bone to maintain serum levels.
Excitation-contraction coupling in muscle
Action potentials trigger sarcoplasmic reticulum calcium release. Released Ca²⁺ binds troponin, exposing actin-binding sites for myosin to drive contraction. Calcium reuptake by SERCA pumps allows relaxation. This calcium cycling occurs millions of times per day in skeletal and cardiac muscle.
Nerve transmission
Calcium influx through voltage-gated calcium channels at the presynaptic terminal triggers neurotransmitter vesicle fusion. Without adequate calcium, synaptic transmission fails. Hypocalcemia causes hyperexcitability through reduced threshold for sodium channel opening — manifests as tetany and cramps.
Blood clotting cascade
Calcium is Coagulation Factor IV. It serves as a cofactor for activation of multiple clotting factors (II, VII, IX, X) and is essential for fibrin formation. EDTA chelation of calcium prevents clotting in lab tubes — illustrating calcium's foundational role.
Cardiac action potential
Calcium current is responsible for the plateau phase of cardiac action potentials. Calcium-induced calcium release from cardiac sarcoplasmic reticulum drives contraction. Hypocalcemia prolongs QT interval; hypercalcemia shortens it. Both extremes increase arrhythmia risk.
Clinical trials
Reanalysis of the Women's Health Initiative limited-access dataset combined with pooled analysis of 13 clinical trials. Updated the 2010 BMJ meta-analysis that first raised concern about calcium supplements and heart attacks. Published in BMJ (342:d2040).
28,072 participants from eight placebo-controlled calcium trials plus the WHI calcium and vitamin D participants who were not already taking their own calcium supplements. Mostly older women.
In the 16,718 WHI women not already taking their own calcium, calcium plus vitamin D raised cardiovascular event rates (hazard ratios 1.13 to 1.22). Pooled with eight calcium trials, calcium with or without vitamin D increased heart attack risk (RR 1.24, 95% CI 1.07 to 1.45) and heart attack or stroke (RR 1.15, 95% CI 1.03 to 1.27). This is a post-hoc reanalysis and its conclusions remain disputed.
Pooled analysis of double-blind placebo-controlled clinical trials evaluating calcium supplementation for cardiovascular disease risk. Published in Nutrients. It pools largely the same older trials (published 1990 to 2013) used in the earlier Bolland analyses, so it is not independent confirmation.
28,935 adults across 13 double-blind placebo-controlled clinical trials (14,692 intervention vs 14,243 control).
Calcium supplementation increased CVD risk (RR 1.15, 95% CI 1.06-1.25) and CHD risk (RR 1.16) vs placebo. The increase was seen specifically in healthy postmenopausal women, including subgroups taking 1,000 mg/day of supplemental calcium. The absolute increase is small. A 2016 review supported by a Pfizer Consumer Healthcare grant through the National Osteoporosis Foundation found no association between calcium intake and cardiovascular risk.
Systematic review and meta-analysis of randomized trials in community-dwelling adults over 50; people in residential care were excluded. Published in JAMA. Distinguished between trial populations more carefully than earlier pooled analyses.
51,145 community-dwelling older adults across 33 clinical trials.
Calcium, vitamin D, or both together were not associated with fewer hip, nonvertebral, vertebral or total fractures versus placebo or no treatment. For calcium alone, hip fracture risk was nonsignificantly higher (RR 1.53, 95% CI 0.97 to 2.42). Results were consistent regardless of dose, dietary calcium intake or baseline vitamin D level. The authors concluded the findings do not support routine use of these supplements in community-dwelling older people.
Foundational randomized double-blind placebo-controlled trial of calcium plus vitamin D in postmenopausal women. Long 7-year intervention captures durable bone outcomes. Among the largest nutrition intervention trials ever conducted in women.
36,282 postmenopausal women aged 50 to 79 randomized to 1,000 mg calcium carbonate plus 400 IU vitamin D3 daily or placebo; average follow-up 7.0 years.
Calcium plus vitamin D raised hip bone density by 1.06 percent versus placebo but did not significantly reduce hip fracture (HR 0.88, 95% CI 0.72 to 1.08) or total fractures (HR 0.96, 95% CI 0.91 to 1.02). Kidney stones increased (HR 1.17, 95% CI 1.02 to 1.34). Hip fracture was lower among women who kept taking the pills (HR 0.71), a non-randomized comparison. The 400 IU vitamin D dose is low by current standards. Reanalysis of this trial's limited-access dataset later contributed to the cardiovascular concern signal that emerged in subsequent pooled analyses.
Two large randomized noninferiority trials conducted in India and Tanzania to evaluate whether 500 mg/day of calcium is noninferior to 1,500 mg/day for pre-eclampsia and preterm birth in low-calcium-intake populations. Published in 2024.
22,000 nulliparous pregnant women (11,000 in each trial) in India and Tanzania, populations with low dietary calcium intake.
Pre-eclampsia occurred in 3.0% (500 mg) vs 3.6% (1,500 mg) in India and 3.0% vs 2.7% in Tanzania, meeting noninferiority in both. For preterm birth the low dose was noninferior in India but not in Tanzania. Both groups took calcium, so these trials compare doses and cannot show whether calcium prevents pre-eclampsia compared with none. Funded by the Bill and Melinda Gates Foundation and others.